Icatibant is not metabolized by CYP enzymes. Nausea is a common side effect that can be potentially porphyrinogenic through reduction in caloric intake.

Icatibant is indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency). A common side effect that can be potentially porphyrinogenic through reduction in carbohydrate intake and that also can be confused with an acute porphyria attack is nausea. Other common side effects are dizziness and headache.

Icatibant is metabolized by proteolytic enzymes. Elimination half-life is 1-2 hours. In vitro studies have shown that icatibant is not metabolized by oxidative metabolic pathways and it is not an inhibitor of CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4, or and inducer of CYP1A2 and CYP3A4 (SPC).